BOPI 05 BR/2024 REPERTOIRE NUMERIQUE 12 La poudre issue du mélange peut être diluée dans de l'eau et être absorbée à raison de 200 ml litres après les repas pour soigner les pathologies telles que par exemple : - Maux de tête, - Rhume, - Asthme, - Congestion pulmonaire, - SARS-CoV, - SARS-Cov 19, - Herpes Virus, - Influenza A virus, - Herpès simplex virus (HSV) - L'absorption du cocktail permet de dégager les muqueuses, d’augmenter l’énergie, de diminuer progressivement le virus et de renforcer le système immunitaire. - Au bout de deux jours d'absorption du produit, les symptômes des pathologies décrites commencent à disparaître. ________________________________________ (11) 21533 Consulter le mémoire (51) A61K 31/422 (2018.01); A61K 31/4439 (2018.01); A61K 9/127 (2018.01); C07D 263/20 (2018.01) (21) 1202200533 - PCT/US2021/038131 (22) 18/06/2021 (30) US n° 63/040,810 du 18/06/2020 et US n° 17/351,631 du 18/06/2021 (54) Oxazolidinone compounds, Liposome compositions comprising Oxazolidinone compounds and methods of use thereof. (72) DRUMMOND, Daryl C. (US); TIPPARAJU, Suresh K. (US); NOBLE, Charles O. (US); KOSHKARYEV, Alexander (US) et KIRPOTIN, Dmitri B. (US) (73) AKAGERA MEDICINES, Inc., 5 Essex Street, BOXFORD, Massachusetts 01921 (US) (74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, The House of Gideon, Golf/Bastos Quater, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM). (57) Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections. ________________________________________ (11) 21534 Consulter le mémoire (51) A61K 31/4168 (2018.01); A61K 31/445 (2018.01); A61K 31/573 (2018.01); A61K 9/00 (2018.01); A61K 9/08 (2018.01); A61K 9/127 (2018.01); A61P 23/00 (2018.01)
RkJQdWJsaXNoZXIy MTM1NDc3MA==